Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ. Valent P, et al. Among authors: vandenberghe p. J Allergy Clin Immunol. 2012 Sep;130(3):607-612.e9. doi: 10.1016/j.jaci.2012.02.019. Epub 2012 Mar 28. J Allergy Clin Immunol. 2012. PMID: 22460074 Free PMC article.
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.
Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, Gotlib J, Horny HP, Simon HU, Klion AD. Valent P, et al. Among authors: vandenberghe p. Expert Rev Hematol. 2012 Apr;5(2):157-76. doi: 10.1586/ehm.11.81. Expert Rev Hematol. 2012. PMID: 22475285 Free PMC article. Review.
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Valent P, et al. Among authors: vandenberghe p. Allergy. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544. Epub 2022 Oct 19. Allergy. 2023. PMID: 36207764 Free PMC article. Review.
ICON: Eosinophil Disorders.
Valent P, Klion AD, Rosenwasser LJ, Arock M, Bochner BS, Butterfield JH, Gotlib J, Haferlach T, Hellmann A, Horny HP, Leiferman KM, Metzgeroth G, Matsumoto K, Reiter A, Roufosse F, Rothenberg ME, Simon HU, Sotlar K, Vandenberghe P, Weller PF, Gleich GJ. Valent P, et al. Among authors: vandenberghe p. World Allergy Organ J. 2012 Dec;5(12):174-81. doi: 10.1097/WOX.0b013e31827f4192. World Allergy Organ J. 2012. PMID: 23282419 Free PMC article. No abstract available.
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P. Sadovnik I, et al. Among authors: vandenberghe p. Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6. Exp Hematol. 2014. PMID: 24407160 Free PMC article. Clinical Trial.
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P, Wlodarska I, Michaux L, Zachée P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Vandenberghe P, et al. Leukemia. 2004 Apr;18(4):734-42. doi: 10.1038/sj.leu.2403313. Leukemia. 2004. PMID: 14973504
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. Cools J, et al. Among authors: vandenberghe p. N Engl J Med. 2003 Mar 27;348(13):1201-14. doi: 10.1056/NEJMoa025217. N Engl J Med. 2003. PMID: 12660384 Free article.
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, Cavalloni C, Bellini M, Milanesi C, Dambruoso I, Astori C, Kralovics R, Vandenberghe P, Cazzola M. Rumi E, et al. Among authors: vandenberghe p. Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23. Ann Hematol. 2015. PMID: 26202607 No abstract available.
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, Knoops L, Constantinescu S, Sigaux F, Meijerink JP, Vandenberghe P, Tartaglia M, Foa R, Macintyre E, Haferlach T, Cools J. Kleppe M, et al. Among authors: vandenberghe p. Blood. 2011 Jun 30;117(26):7090-8. doi: 10.1182/blood-2010-10-314286. Epub 2011 May 6. Blood. 2011. PMID: 21551237 Free article.
303 results